文献速递血栓与止血

绝经前女性首次静脉血栓事件后使用激素类避孕药与复发风险

Hormonal contraceptive use after a first venous thrombotic event and the risk of recurrence in premenopausal women.
PubMed 文献 · J Thromb Haemost · 2024-03-28

本研究基于1999至2004年纳入的绝经前首次静脉血栓栓塞症(VTE)女性,随访至2010年,评估激素类避孕药(HC)使用与VTE复发风险。结果示抗凝治疗期间复方HC(CHC)使用与不使用的复发风险无clear差异(HR 0.8,95%CI 0.1-8.2),停抗凝后CHC使用较不使用者复发风险高2.4倍(HR 2.4,95%CI 1.2-5.0);左炔诺孕酮宫内节育器使用与不使用者复发风险相似(HR 0.9,95%CI 0.3-3.1)。

要点

  • 抗凝治疗期间CHC使用与不使用者VTE复发风险无clear差异(HR 0.8,95%CI 0.1-8.2)。
  • 停抗凝后CHC使用较不使用者VTE复发风险高2.4倍(HR 2.4,95%CI 1.2-5.0)。
  • 左炔诺孕酮宫内节育器使用与不使用者VTE复发风险相似(HR 0.9,95%CI 0.3-3.1)。

核心结论

  • 首次VTE后使用CHC在抗凝治疗期间是安全的,但在无抗凝治疗时大幅增加VTE复发风险。
  • 本研究为左炔诺孕酮宫内节育器作为安全替代选择增添了证据。

研究设计与样本

  • 研究纳入1999至2004年间多环境与遗传评估静脉血栓研究中的绝经前首次VTE女性,随访至2010年。
  • 通过链接荷兰药物统计基金会获取HC使用数据,采用时间依赖Cox比例风险模型估计风险比(HR)及95%CI。
  • 共650名女性唯一链接并随访,总随访3538人年(中位6.1年),期间发生57例VTE复发。

主要发现

  • 57例VTE复发中5例(8.8%)发生在抗凝治疗期间,CHC使用与不使用者复发风险无clear差异(HR 0.8,95%CI 0.1-8.2)。
  • 停抗凝后,CHC使用较不使用者VTE复发风险高2.4倍(HR 2.4,95%CI 1.2-5.0)。
  • 左炔诺孕酮宫内节育器使用与不使用者VTE复发风险相似(HR 0.9,95%CI 0.3-3.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extensive evidence is available on hormonal contraceptive (HC) use and the risk of a first venous thromboembolism (VTE) event. Despite recommendations to discontinue combined HC (CHC) use, some women continue or start its use after a first VTE. OBJECTIVES: We aimed to evaluate the VTE recurrence risk associated with HC use in premenopausal women. METHODS: Premenopausal women with a first VTE included in the Multiple Environmental and Genetic Assessment of Venous Thrombosis study between 1999 and 2004 were followed for a recurrence until 2010. Data on HC use were available through linkage to the Dutch Foundation for Pharmaceutical Statistics. The risk of recurrence was assessed 1) during anticoagulant therapy and 2) after cessation of anticoagulant therapy. Time-dependent Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% CIs adjusted for age and body mass index at baseline and thromboprophylaxis use during follow-up. RESULTS: Six hundred fifty women were uniquely linked and followed for a total of 3538 person-years (median, 6.1 years), during which 57 VTE recurrences occurred. Five occurred (8.8%) during anticoagulation treatment, with no clear risk difference for CHC use vs nonuse (HR, 0.8; 95% CI, 0.1-8.2). After anticoagulation cessation, CHC use was associated with a 2.4-fold higher risk of recurrence (HR, 2.4; 95% CI, 1.2-5.0) compared with nonuse. Recurrence risk for levonorgestrel-releasing intrauterine device use was similar to that for nonuse (HR, 0.9; 95% CI, 0.3-3.1). CONCLUSION: CHC use after a first VTE is safe during anticoagulant use but substantially increases the risk of a recurrent VTE event in absence of anticoagulant use. This study adds to the evidence regarding the use of a levonorgestrel-releasing intrauterine device as a safe alternative.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Verlaan JPL, Stegeman BH, Timp JF, et al. Hormonal contraceptive use after a first venous thrombotic event and the risk of recurrence in premenopausal women. J Thromb Haemost. 2024. PMID: 38554933. doi:10.1016/j.jtha.2024.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。